IBO
vs
S
S&P TSX Composite Index (Canada)
IBO
Over the past 12 months, IBO has underperformed S&P TSX Composite Index (Canada), delivering a return of -80% compared to the S&P TSX Composite Index (Canada)'s +33% growth.
Stocks Performance
IBO vs S&P TSX Composite Index (Canada)
Performance Gap
IBO vs S&P TSX Composite Index (Canada)
Performance By Year
IBO vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Universal Ibogaine Inc
Glance View
Universal Ibogaine, Inc. develops ibogaine based drug franchise to treat addiction and related mental health issues. The company is headquartered in Calgary, Alberta. The company went IPO on 2017-06-21. The firm is focused on developing medicines and building a network of holistic recovery clinics for the treatment of addictions. The company treats addictions primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. Its focuses on developing ibogaine for the treatment of opioid use disorders. Ibogaine is a neuroactive compound, which is derived from various plants. Ibogaine helps to repair damaged brain tissues of the patients and helps them to recover and rebuild their lives.
